Arcutis Biotherapeutics, Inc. (ARQT)

Market Cap	3.56B
Revenue (ttm)	317.93M
Net Income (ttm)	-44.32M
Shares Out	122.49M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	76.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,873,613
Open	28.08
Previous Close	28.08
Day's Range	28.08 - 29.67
52-Week Range	11.13 - 31.77
Beta	1.70
Analysts	Strong Buy
Price Target	24.83 (-14.5%)
Earnings Date	Oct 28, 2025

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2020
• Employees: 342
• Stock Exchange: NASDAQ
• Ticker Symbol: ARQT
• Website: https://www.arcutis.com

Financial Performance

In 2024, Arcutis Biotherapeutics's revenue was $196.54 million, an increase of 229.74% compared to the previous year's $59.61 million. Losses were -$140.04 million, -46.58% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price target is $24.83, which is a decrease of -14.50% from the latest price.

Price Target

$24.83

(-14.50% downside)

Analyst Consensus: Strong Buy